Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2019, specifically dated May 1, 2019. The document serves as a transaction notification regarding share allocations for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Instrument | Price | Total Volume | Transaction Date |
|---|---|---|---|
| Ordinary Shares (GBP) | £15.68 | 3,646.951 | 2019-05-01 |
| American Depositary Shares (USD) | $40.67 | 3,388.541 | 2019-05-01 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share allocation transactions for Independent Non-Executive Directors covering the service period from January 1, 2019, to March 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a regulatory disclosure of director share acquisitions.
Investor Verification Points
- Verify the total number of Ordinary Shares and ADSs allocated to directors as compensation for the Q1 2019 service period.
- Confirm the transaction price of £15.68 per Ordinary Share and $40.67 per ADS reflects the market value on the transaction date.
- Note that these are "notional" share acquisitions under specific allocation arrangements, not open market purchases by the directors.